Press Releases

News from the year: /2013

Interim results for the six months ended 30 June 2019

Oxford, UK – 4 September 2019: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2019. FINANCIAL HIGHLIGHTSRevenues were £32.1 million, a decrease of 9% (H1 2018: £35.3 million)… Read More

Read more

Oxford Biomedica and Santen enter R&D collaboration and Option & Licence Agreement for development of gene therapy vectors for inherited retinal disease

June 26, 2019, Oxford, UK and Osaka Japan–Oxford Biomedica plc (LSE:Oxford Biomedica), a leading gene and cell therapy group, and Santen Pharmaceutical Co., Ltd. (Santen), the market leader for prescription ophthalmic pharmaceuticals in Japan with a global presence in over 60 countries, today announced that they have entered into an… Read More

Read more

Exercise of Subscription Option by Novo Holdings

Oxford, UK – 29 May 2019: Oxford Biomedica plc (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces that, further to the announcement of 28 May in relation to Novo Holdings’ agreement to subscribe for 6,568,024 new ordinary shares in Oxford Biomedica (the “Subscription Shares”) at a… Read More

Read more

Oxford Biomedica announces R&D collaboration with Microsoft to improve gene and cell therapy manufacturing using the intelligent cloud and machine learning

Oxford, UK – 12 March 2019: Oxford Biomedica plc (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces that it has entered into a research and development collaboration with Microsoft Research to improve the yield and quality of next generation gene therapy vectors using the cloud and machine… Read More

Read more

Notice of Preliminary Results

London, UK – 8 February 2019: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, will be announcing its Preliminary Results for the year ended 31 December 2018 on Thursday 14 March 2019. A briefing for analysts will be held at 12:00pm… Read More

Read more